Opportunities for Healthy Volunteers

Contribute to medical research by participating in studies designed for healthy participants in your selected area.

Matched clinical trials

  • Study on Vinorelbine for Patients with Metastatic Colorectal Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    Italy
  • Study on the Safety and Effectiveness of Nivolumab and Ipilimumab for Patients with Metastatic Colorectal Cancer with dMMR or MSI

    Not yet recruiting

    2 1 1 1
    Investigated Drugs:
    France
  • Study on the Effectiveness of Floxuridine in Patients with Resectable Colorectal Liver Metastases and Low Clinical Risk Score

    Not yet recruiting

    3 1 1 1
    The Netherlands
  • Study of LB-100 and Azenosertib for Patients with Metastatic Colorectal Cancer

    Not yet recruiting

    1 1 1
    Investigated Diseases:
    The Netherlands
  • Phase III Study Comparing FOLFOX Plus Panitumumab Followed by FOLFIRI Plus Bevacizumab Versus FOLFOX Plus Bevacizumab Followed by FOLFIRI Plus Panitumumab in Wild-Type RAS Metastatic Colorectal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Portugal Spain
  • A Study Comparing Telisotuzumab Adizutecan to Trifluridine, Tipiracil, and Bevacizumab in Adults with Refractory Metastatic Colorectal Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    France Germany Italy The Netherlands Poland Spain
  • Study of Pembrolizumab and Temozolomide for Patients with Metastatic Colorectal Cancer Who Have Not Responded to Standard Treatments

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Italy
  • Study of Galunisertib and Capecitabine for Patients with Advanced Chemotherapy-Resistant Colorectal Cancer with Peritoneal Metastases

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    The Netherlands
  • Study on Methadone Hydrochloride and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

    Not recruiting

    1 1 1 1
    Germany
  • Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

    Not recruiting

    2 1 1 1
    Belgium Czechia Denmark France Germany Italy +6